Structured Review

Roche hcv ribonucleic acid rna
The laboratory testing algorithm used for identifying hepatitis C virus and hepatitis B virus infection. HBV = hepatitis B virus, HBc = hepatitis B core; HBs = hepatitis B surface; <t>HCV</t> = hepatitis C virus; <t>RNA</t> = ribonucleic acid.
Hcv Ribonucleic Acid Rna, supplied by Roche, used in various techniques. Bioz Stars score: 94/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hcv ribonucleic acid rna/product/Roche
Average 94 stars, based on 2 article reviews
Price from $9.99 to $1999.99
hcv ribonucleic acid rna - by Bioz Stars, 2020-04
94/100 stars

Images

1) Product Images from "Detecting Hepatitis B and C by Combined Public Health and Primary Care Birth Cohort Testing"

Article Title: Detecting Hepatitis B and C by Combined Public Health and Primary Care Birth Cohort Testing

Journal: Annals of Family Medicine

doi: 10.1370/afm.2166

The laboratory testing algorithm used for identifying hepatitis C virus and hepatitis B virus infection. HBV = hepatitis B virus, HBc = hepatitis B core; HBs = hepatitis B surface; HCV = hepatitis C virus; RNA = ribonucleic acid.
Figure Legend Snippet: The laboratory testing algorithm used for identifying hepatitis C virus and hepatitis B virus infection. HBV = hepatitis B virus, HBc = hepatitis B core; HBs = hepatitis B surface; HCV = hepatitis C virus; RNA = ribonucleic acid.

Techniques Used: Infection

Related Articles

Positive Control:

Article Title: Prevalence of Hepatitis B, Hepatitis C, and HIV in Multiply Transfused Sickle Cell Disease Patients from Oman
Article Snippet: In these assays specimens were considered positive if they demonstrated reactivity to two or more antigen bands at an intensity higher than or equal to the weak positive control. .. HCV ribonucleic acid (RNA) was tested on samples using the RT-PCR kit COBAS® AMPLICOR HCV Test, Version 2.0 (Roche Molecular Systems Inc., Pleasanton, California, USA).

Infection:

Article Title: Detecting Hepatitis B and C by Combined Public Health and Primary Care Birth Cohort Testing
Article Snippet: Two hotspots were targeted because of their highest regional estimated prevalence of HCV infection. .. When a screening test was positive, subsequent tests included the following: HCV ribonucleic acid (RNA) (COBAS, Ampliprep/COBAS, Taqman HCV Quantitative Test, version 2.0, Roche Diagnostics) and/or immunoblot (Mikrogen), a hepatitis B surface antigen (HBsAg) test, and an antihepatitis B surface (anti-HBs) test (HBsAg II and Anti-HBs, Roche Diagnostics) (see ).

Article Title: Prevalence of Hepatitis B, Hepatitis C, and HIV in Multiply Transfused Sickle Cell Disease Patients from Oman
Article Snippet: HCV ribonucleic acid (RNA) was tested on samples using the RT-PCR kit COBAS® AMPLICOR HCV Test, Version 2.0 (Roche Molecular Systems Inc., Pleasanton, California, USA). .. HBV infection was ascertained by assaying for HBeAg and HBsAg using enzyme-linked immunosorbent assay (Axsym, Abbott Laboratories).

Enzyme-linked Immunosorbent Assay:

Article Title: Prevalence of Hepatitis C among Multi-transfused Thalassaemic Patients in Oman
Article Snippet: All sera which were repeatedly reactive by ELISA were subjected to additional testing by RIBA. .. HCV ribonucleic acid (RNA) was tested on samples using the RT-PCR kit COBAS® AMPLICOR HCV Test, Version 2.0 (Roche Molecular Systems Inc., Pleasanton, California, USA).

Reverse Transcription Polymerase Chain Reaction:

Article Title: Prevalence of Hepatitis C among Multi-transfused Thalassaemic Patients in Oman
Article Snippet: .. HCV ribonucleic acid (RNA) was tested on samples using the RT-PCR kit COBAS® AMPLICOR HCV Test, Version 2.0 (Roche Molecular Systems Inc., Pleasanton, California, USA). .. In 2009, SQUH started testing samples for HCV RNA using quantitative COBAS® TaqMan® analysers (Roche Molecular Systems Inc.) with a linear quantification range between 43 and 6.9 × 107 IU/mL and a lower limit of detection of 12.6 IU/mL.

Article Title: Prevalence of Hepatitis B, Hepatitis C, and HIV in Multiply Transfused Sickle Cell Disease Patients from Oman
Article Snippet: .. HCV ribonucleic acid (RNA) was tested on samples using the RT-PCR kit COBAS® AMPLICOR HCV Test, Version 2.0 (Roche Molecular Systems Inc., Pleasanton, California, USA). .. Since 2009, HCV RNA was tested using quantitative COBAS® TaqMan® analyzers (Roche Molecular Systems Inc.) with a linear quantification range between < 15 and 100 × 106 IU/mL and a lower limit of detection of 12.6 IU/mL.

T-Test:

Article Title: Prevalence of Hepatitis C among Multi-transfused Thalassaemic Patients in Oman
Article Snippet: HCV ribonucleic acid (RNA) was tested on samples using the RT-PCR kit COBAS® AMPLICOR HCV Test, Version 2.0 (Roche Molecular Systems Inc., Pleasanton, California, USA). .. For continuous variables, means and standard deviations were used to summarise the variables while analysis was conducted using Student’s t-test.

Electrochemiluminescence:

Article Title: Prevalence of Hepatitis B, Hepatitis C, and HIV in Multiply Transfused Sickle Cell Disease Patients from Oman
Article Snippet: In case of HCV (anti-HCV) serological markers were screened by Architect HCV Ag Test (Architect HCV Ag Test, Abbot, Germany), and if positive were confirmed by second confirmatory method, the electrochemiluminescence immunoassay on Cobas e 411 immunoassay analyzer. .. HCV ribonucleic acid (RNA) was tested on samples using the RT-PCR kit COBAS® AMPLICOR HCV Test, Version 2.0 (Roche Molecular Systems Inc., Pleasanton, California, USA).

Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96
    Roche hcv rna
    Longitudinal virological results following discordant or inconsistent TMA results at week 12 or week 20 of treatment Patients included in this analysis were those who: (left panel) had <t>HCV</t> <t>RNA-positive</t> results at baseline, had TMA-discordant (+/-) results at week 12, and subsequent virological results available at weeks 20 OR, (right panel) had HCV RNA-positive results at week 12, had TMA-discordant (+/-) results at week 20, and subsequent virological results available at week 24. Positive samples (+) were defined as those that were PCR-positive or TMA-positive (singly or in duplicate). Negative samples (-) were defined as those that were TMA-negative (singly or in duplicate). TMA-discordant or inconsistent results at both weeks 12 and 20 were more likely to be followed by TMA-negative than positive results (19 negative vs 2 positive, p
    Hcv Rna, supplied by Roche, used in various techniques. Bioz Stars score: 96/100, based on 152 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hcv rna/product/Roche
    Average 96 stars, based on 152 article reviews
    Price from $9.99 to $1999.99
    hcv rna - by Bioz Stars, 2020-04
    96/100 stars
      Buy from Supplier

    Image Search Results


    Longitudinal virological results following discordant or inconsistent TMA results at week 12 or week 20 of treatment Patients included in this analysis were those who: (left panel) had HCV RNA-positive results at baseline, had TMA-discordant (+/-) results at week 12, and subsequent virological results available at weeks 20 OR, (right panel) had HCV RNA-positive results at week 12, had TMA-discordant (+/-) results at week 20, and subsequent virological results available at week 24. Positive samples (+) were defined as those that were PCR-positive or TMA-positive (singly or in duplicate). Negative samples (-) were defined as those that were TMA-negative (singly or in duplicate). TMA-discordant or inconsistent results at both weeks 12 and 20 were more likely to be followed by TMA-negative than positive results (19 negative vs 2 positive, p

    Journal: Hepatology (Baltimore, Md.)

    Article Title: Interpretation of Positive TMA Test Results from PCR-Negative Samples Obtained after Treatment of Chronic Hepatitis C

    doi: 10.1002/hep.22487

    Figure Lengend Snippet: Longitudinal virological results following discordant or inconsistent TMA results at week 12 or week 20 of treatment Patients included in this analysis were those who: (left panel) had HCV RNA-positive results at baseline, had TMA-discordant (+/-) results at week 12, and subsequent virological results available at weeks 20 OR, (right panel) had HCV RNA-positive results at week 12, had TMA-discordant (+/-) results at week 20, and subsequent virological results available at week 24. Positive samples (+) were defined as those that were PCR-positive or TMA-positive (singly or in duplicate). Negative samples (-) were defined as those that were TMA-negative (singly or in duplicate). TMA-discordant or inconsistent results at both weeks 12 and 20 were more likely to be followed by TMA-negative than positive results (19 negative vs 2 positive, p

    Article Snippet: Subjects with detectable HCV RNA at week 20 by PCR were deemed to be nonresponders to peginterferon/ribavirin and treatment was discontinued at week 24.

    Techniques: Polymerase Chain Reaction